A retrospective analysis of changing from alternative agents to carbamazepine extended-release capsules in bipolar disorder

Annals of Clinical Psychiatry

Volumn 18, Issue SUPPL. 1, 2006, Pages 31-34

  Ginsberg, Lawrence D ^a  

^a Red Oak Psychiatry Associates   (United States)

Author keywords

Bipolar disorder; Carbamazepine; Switching

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; VALPROIC ACID;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; BIPOLAR DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL OBSERVATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NAUSEA; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RASH; RELAPSE; RETROSPECTIVE STUDY; SCORING SYSTEM; SOMNOLENCE; TABLET; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CAPSULES; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 33744998713     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230600653452     Document Type: Article

References (14)

1. Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD: Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64:53-59
2. McElroy SL, Keck PE Jr: Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48:539-557
3. Sachs GS: Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychophannacol 1996; 16(2 suppl 1):32S-47S
4. Zornberg GL, Pope HG Jr: Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993; 13:397-408
5. Preskorn SH: How drug-drug interactions can impact managed care. Am J Manag Care 2004; 10(6 suppl):S186-S198
6. Flowers CR, Veenstra D: The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004; 22:481-493
7. Keck PE Jr, McElroy SL, Nemeroff CB: Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4:395-405
8. Ballenger JC, Post RM: Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137:782-790
9. Greenberg RN: Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6:592-599
10. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 suppl):1-50
11. Weisler RH, Kalali AH, Ketter TA, and the SPD417 Study Group: A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:478-484
12. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA: Extended-release carbamazepine for treatment of manic and mixed symptoms. Presented at the 157th American Psychiatric Association Annual Meeting; May 1-6, 2004; New York, NY
13. Ketter TA, Kalali AH, Weisler RH, for the SPD417 Study Group: A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:668-673
14. Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter T, Keck P, Swann A, Kalali A: Efficacy of extended-release carbamazepine in bipolar disorder: results of two pooled clinical trials. Presented at the US Psychiatric and Mental Health Congress; November 18-21, 2004; San Diego, CA